New lenvatinib and pembrolizumab combination for metastatic renal cell carcinoma in 1 st  line drug treatment: comparative effectiveness and safety

B. Ya. Alekseev; I. M. Shevchuk

Cancer Urology
Onkourologiâ

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

User

eng | рус

Cancer Urology

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Alekseev B.Ya., Shevchuk I.M. New lenvatinib and pembrolizumab combination for metastatic renal cell carcinoma in 1^st line drug treatment: comparative effectiveness and safety. Cancer Urology. 2022;18(3):51-59. (In Russ.) https://doi.org/10.17650/1726-9776-2022-18-3-51-59

Views PDF (Rus): 360

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles

Editor-in-Chief

Boris Ya. Alekseev

About the Authors

B. Ya. Alekseev
National Medical Research Radiological Center, Ministry of Health of Russia; Medical Institute of Continuing Education, Moscow State University of Food Production
Russian Federation

3 2^nd Botkinskiy Proezd, Moscow 125284;
11 Volokolamskoe Shosse, Moscow 125080

I. M. Shevchuk
Medical Institute of Continuing Education, Moscow State University of Food Production; N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation

Irina Musaevna Shevchuk

11 Volokolamskoe Shosse, Moscow 125080;
Build. 1, 51 3^rd Parkovaya St., Moscow 105425